Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Hazard Ratio01:12

Hazard Ratio

90
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
90
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

150
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
150
Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

98
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
98
Actuarial Approach01:20

Actuarial Approach

63
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
63

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

JNCI cancer spectrum·2026
Same author

Learning to share nicely: Leveraging the Nobel Prize-winning Shapley value to enhance collaboration and cooperation in healthcare systems.

Future healthcare journal·2026
Same author

Purification of aqueous fluids from basic fuchsine employing a new polymer of CMC-CMS hydrogel mixture: sustainability perspective.

BMC chemistry·2026
Same author

Decomposing the effects of changes of population size, age-sex profile, health status and residual factors on growth in hospital activity in English hospitals: an ecological database study from 2011-2019.

BMC health services research·2025
Same author

Cross-cultural adaptation of patient-reported outcome measures: Methodological guidance for a better practice.

Research in social & administrative pharmacy : RSAP·2025
Same author

Correction: Non-invasive geophysical imaging reveals Ptolemaic tombs at Al-Dyabat for global archaeological applications.

Scientific reports·2025

Related Experiment Video

Updated: Jun 5, 2025

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K

IAPN: a simple framework for evaluating whether a population-based risk stratification tool will be cost-effective

Steven Wyatt1, Mohammed A Mohammed2,3, Peter Spilsbury2

  • 1The Strategy Unit - NHS Midlands and Lancashire Commissioning Support Unit, Birmingham, UK. swyatt@nhs.net.

Cost Effectiveness and Resource Allocation : C/E
|December 5, 2024
PubMed
Summary
This summary is machine-generated.

Evaluating healthcare risk prediction tools requires assessing cost-effectiveness alongside statistical performance. A new framework integrates positive predictive value (PPV) and intervention effectiveness (NNT) to determine economic viability before implementation.

Keywords:
CostDesign stage evaluationInterventionNumber needed to treatPositive predictive valueRisk prediction

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

Related Experiment Videos

Last Updated: Jun 5, 2025

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

Area of Science:

  • Healthcare Analytics
  • Clinical Decision Support
  • Health Economics

Background:

  • Risk prediction tools are crucial for identifying high-risk patients but often lack cost-effectiveness evaluation.
  • Traditional performance metrics (sensitivity, specificity) do not guarantee real-world efficacy or cost savings.

Discussion:

  • A novel framework is proposed to evaluate risk prediction tools during the design phase.
  • This framework integrates Positive Predictive Value (PPV) with intervention effectiveness, measured by Number Needed to Treat (NNT).

Key Insights:

  • The cost-effectiveness criterion is defined as: Intervention Cost (I) < Adverse Event Cost (A) * (PPV / NNT).
  • This provides a quantitative method to assess the economic value of risk prediction tools.

Outlook:

  • Enables informed decision-making for implementing cost-effective risk prediction tools.
  • Facilitates the integration of economic evaluations early in the tool development lifecycle.